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Abstract
Background: Paragangliomas and pheochromocytomas are sympathetic or parasympathetic tumors derived from
the paraganglia and the adrenal medulla, respectively. Paragangliomas and pheochromocytomas can be sporadic
or familial, the latter frequently being multifocal and possibly due to succinate dehydrogenase complex genes
mutations. In addition, 12% of sporadic paragangliomas are related to covered succinate dehydrogenase complex
mutations. The importance of identifying succinate dehydrogenase complex mutations is related to the risk for
these patients of developing multiple tumors, including non-endocrine ones, showing an aggressive clinical
presentation.
Case presentation: We report the case of a 45-year-old Caucasian man with an indolent mass in his neck. Ultrasound
of his neck, magnetic resonance imaging, and 1,4,7,10-tetraazacyclododecane-N(I),N(II),N(III),N(IIII)-tetraacetic acid(D)-
Phe(1)-thy(3)-octreotide (68Ga-DOTATOC) positron emission tomography-computed tomography and endocrine work-
up were consistent with a carotid body paraganglioma with concomitant nodal enlargement in several body regions,
which turned out to be a follicular lymphoma at histology. He was found to carry a germline Succinate dehydrogenase
subunit B gene (SDHB) mutation.
Conclusion: It is crucial to look for a second malignancy in the case of a paraganglioma demonstrating succinate
dehydrogenase complex germline mutations.
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Background
The terms paraganglioma (PGL) and pheochromocytoma
(PHEO) refer to sympathetic or parasympathetic tumors
arising from the paraganglia and the adrenal medulla, re-
spectively [1–3]; PGL and PHEO together are named as
PPGL. The annual incidence of PPGL is up to 3/million
population [4]. Hereditary PPGLs represent 40% of the
cases and are characterized by multifocal lesions in 35–
50% of the patients [1, 3, 5, 6]. Succinate dehydrogenase
(SDH) germline mutations represent a possible cause of
hereditary PPGL, but have also been reported in 12% of
sporadic cases [1]. Germline mutations in SDHB, SDHC,
and SDHD genes have been found in PPGL, but also in
gastrointestinal stromal tumors [2, 7]. Genetic screening
of patients with SDH is crucial since hereditary forms are
associated with a dismal prognosis and a high risk of de-
veloping other tumors [2, 3]. In particular, SDHB germline
mutations show significant malignancy rates, which are
higher than those found in patients with PPGL bearing
different SDH germline mutations [8].
This case report describes the association of a neck
PGL with a follicular lymphoma in a patient with a
germline SDHB mutation.
Case presentation
We report the case of a 45-year-old Caucasian man pre-
senting with an indolent mass in his neck of 4 months’
duration, who was otherwise in good clinical condition.
He did not take any prescribed medications and did not
report any history of allergy, tobacco smoking, fever,
sweating, headache, or hypertension. Familial anamnesis
was negative. At a physical examination his thyroid
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appeared normal, while a subcutaneous 2 cm swelling of
his neck was present at the superior margin of the right
sternocleidomastoid muscle. The mass was indolent and
of parenchymatous consistency at palpation, mobile with
respect to the surrounding planes. Palpation also re-
vealed a right submandibular 1.5 cm lymph node en-
largement. Routine laboratory parameters were normal.
He was subjected to ultrasonography (US) of his neck,
which showed a 2.2 × 2.2 × 1.7 cm homogeneously hypoe-
choic oval lesion at the carotid bifurcation, with clear-cut
margins, markedly vascularized at color-Doppler US. His
thyroid had normal morphology and volume, while bilat-
eral lymph node enlargement was observed at lateral cer-
vical level II, devoid of characteristics suspicious for
metastases (Fig. 1).
An endocrine work-up was requested, including urinary
24-hour catecholamines and metanephrines, plasma cal-
cium, phosphate, parathyroid hormone, and chromogra-
nin A; all were found to be in the normal range.
He underwent magnetic resonance imaging (MRI) of
his neck that showed a 2.3 × 2.5 cm neck mass, isoin-
tense to the muscular tissue on T1-weighted images
(T1-wi) and hyperintense on T2-weighted images (T2-
wi). After contrast administration the lesion showed
marked vascularization and intralesional serpiginous
areas. Several bilateral cervical lymph nodes were ob-
served with axial maximum diameter of 1.2 × 0.8 cm and
1 × 0.9 cm at the I and II levels (Fig. 2).
On the basis of US and MRI, a PGL was suspected. A 1,
4,7,10-tetraazacyclododecane-N(I),N(II),N(III),N(IIII)-tet-
raacetic acid(D)-Phe(1)-thy(3)-octreotide (68Ga-DOTA-
TOC) positron emission tomography (PET)-computed
tomography (CT) evaluation was performed, showing an
intense focal uptake with a maximum standardized uptake
value (SUVmax) of 92.4. Weak lymph node uptake was
found in the following regions: lateral cervical, hilar-
mediastinal, peribronchial, axillary, and inguinal stations,
with a SUVmax of 3.9 in the pulmonary left hilum (Fig. 3).
According to current guidelines [3], our patient was
submitted to genetic testing, including investigation for
germline RET and succinate dehydrogenase complex
(SDHx) mutations. Germline RET mutation testing was
performed by direct sequencing as described before [9]
and did not disclose any significant mutation. Germline
SDHx mutation testing was performed on leukocyte
DNA by a next-generation sequencing (NGS) method
based on capture technology (probe; IDT), evaluating
the presence of point mutations, small deletions, or in-
sertion mutations in the coding region of the SDHB,
Fig. 1 Neck ultrasonography (a) and b ultrasonography B-mode paraganglioma images; c axial color-Doppler ultrasonography image
Fig. 2 Neck magnetic resonance imaging. a Axial T1-weighted
sequence; b axial T2-weighted image; c, d axial and sagittal images
after contrast enhancement; e coronal short tau inversion recovery
sequence; f diffusion-weighted sequence
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SDHA, SDHD, SDHAF2, SDHC genes and flanking in-
tronic regions by amplification and direct sequencing.
The results of the genetic test of our patient showed the
presence of a germline mutation in exon 7 of the SDHB
gene. The sequence variant c.689>A; p.Arg230His in
heterozygosis was confirmed in a second genomic DNA
sample. This variant causes the replacement of the
amino acid arginine with a histidine at SDHB protein
codon 230. The arginine residue is highly conserved in
the course of evolution. Moreover, this variant is present
in the population database with a very low frequency,
having been identified in one allele out of 251.416 stud-
ied. This variant is reported by multiple sources as
causative, being classified as pathogenetic, and associated
with PGL. The family history of our patient was negative
for PPGL or other endocrine neoplasms.
Our patient underwent surgery and histology was con-
sistent with a carotid body PGL. Due to the presence of a
germline SDHB gene mutation, a second malignancy was
suspected; therefore, accurate histology examination was
also pursued for the neck lymph nodes resected during
surgery. In fact, a follicular lymphoma was documented as
grade 1 according to the histological classification of the
World Health Organization (WHO). The hematological
assessment of our patient followed European Society for
Medical Oncology (ESMO) guidelines; therefore, a
contrast-enhanced CT scan of his neck, thorax, abdomen,
and pelvis with an 18FDG (18F-fluorodeoxyglucose)-PET
examination established a stage IIIA in accordance with
the Ann Arbor classification system [10]. A clinical
follow-up with blood test (including a complete blood
count, creatinine, uric acid, aspartate aminotransferase,
lactate dehydrogenase, total protein, serum protein elec-
trophoresis, and beta-2 microglobulin) and US examin-
ation at 3 months was performed, the results were normal.
Chemotherapy was not deemed necessary.
Discussion and conclusions
This case report underlines the importance of genetic
screening in patients with PPGL, since second malignan-
cies associated with hereditary forms are not rare. Most
sporadic PGLs are benign and their prognosis is related
to the tumor site: those arising at the carotid body have
a better outcome as compared to those located at the
skull base (jugular foramen, middle ear, and along the
vagus nerve) [11]. A carotid PGL in a SDHB gene muta-
tion carrier is rarely the first manifestation, since SDHB-
related PGLs are usually found in extra-adrenal abdom-
inal sites [8]. In fact, these tumors frequently produce
high amounts of catecholamines, with associated PHEO-
like clinical manifestations. By contrast, our patient
showed a hypervascular, well-circumscribed, and asymp-
tomatic enlarging soft tissue lesion in his neck, without
adrenergic symptoms such as hypertension, headache,
Fig. 3 1,4,7,10-tetraazacyclododecane-N(I),N(II),N(III),N(IIII)-tetraacetic acid(D)-Phe(1)-thy(3)-octreotide (68Ga-DOTATOC) positron emission
tomography/computed tomography axial fused images findings. a Intense focal uptake (maximum standardized uptake value 92.4) in the neck
mass, strongly suggestive of paraganglioma; b hilar-mediastinal and peribronchial weak uptake (maximum standardized uptake value 3.9 in the
pulmonary left hilum); c axillary and d inguinal weak uptake
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shaking, or weight loss. In our case, clinical manifest-
ation was more consistent with a sporadic PGL that is
mostly asymptomatic; when not, it may manifest clinic-
ally either as lateral cervical pulsatile mass or with symp-
toms (dysphagia, anisocoria, dysphonia, and deafness)
due to compression and/or displacement of neighboring
nerve structures [12]. Once again, our case underlines
the importance of a correct genetic investigation, even in
the absence of family history and of specific symptoms.
On the other hand, imaging was highly suggestive be-
cause in our patient the carotid body PGL appeared at
US as a solid, hypoechoic, ovoid, well-defined mass, with
a homogeneous structure; at Doppler US the mass ap-
peared markedly hypervascular [13]. Similarly, MRI was
highly indicative of PGL, since the tumor had a low to
intermediate signal intensity on T1-wi and proton
density-weighted sequences and a markedly high signal
intensity on T2-wi. On the other hand, the pathogno-
monic “salt-and-pepper” pattern was not evident, in
keeping with its inconstant presence [11].
Since a PGL was suspected, in the absence of
catecholamine-related symptoms and of evidence of ele-
vated urinary catecholamine levels, the choice for a
68Ga-DOTATOC PET/CT was appropriate, since 123I-
metaiodobenzylguanidine (MIBG) PET or 18F-DOPA
PET/CT may return false negative results [14]. On the
other hand, 68Ga-DOTATOC PET/CT may identify le-
sions different from PGL and in this case showed mul-
tiple lymph node faint uptake sites. However, an US
examination did not indicate a metastatic suspicion, and,
together with 68Ga-DOTATOC PET/CT, pointed to the
presence of inflammatory lymph nodes. On the basis of
the results of the genetic testing and of the presence of
abdominal 68Ga-DOTATOC PET/CT uptake, a second
malignancy could not be ruled out, supporting the indi-
cation for lymphadenectomy during PGL surgery. In
fact, a follicular lymphoma was discovered. It has been
previously reported that follicular lymphomas express
somatostatin receptors, in keeping with 68Ga-DOTA-
TOC PET uptake in our case [15].
Among the reported malignancies associated with SDHx
mutations, the presence of a malignant B cell lymphoma
has been reported only in one Japanese patient bearing a
G106D alteration in exon 4 of the SDHD gene, who devel-
oped the disease 5 years after PGL surgery [16]. In
addition, genetic derangements in the SDHD gene have
been found in other cases: a silent single nucleotide poly-
morphism was identified in three Burkitt’s lymphoma cell
lines and in one Burkitt’s lymphoma sample [1, 17].
The association of a SDHB germline mutation with
lymphoproliferative disorders, however, is not novel.
Cases of SDHB carriers with T cell acute lymphoblastic
leukemia [18] or Hodgkin lymphoma [19] have been re-
ported. In addition, patients with PGL with synchronous
or metachronous low-grade B cell non-Hodgkin lymph-
oma [20] and follicular lymphoma [21] have been de-
scribed, but germline mutations were not investigated.
Therefore, our case represents the first association be-
tween a SDHB germline mutation and a follicular
lymphoma. To date, studies reporting a predisposition to
lymphoid malignancies in patients with SDHx mutations
are still lacking; also, SDHx genes are not routinely eval-
uated in individuals with non-endocrine cancers [19].
We conclude that in cases of hereditary PPGLs, other
malignancies should be looked for, including hematological
disorders.
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